{"entity":{"id":"nct04711135","kind":"trial","name":"Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs","aka":["NETTER-P"],"tldr":"A phase 2 trial of Lutetium-177 dotatate in pheochromocytoma and paraganglioma, run by Advanced Accelerator Applications, active and no longer recruiting.","summary":"Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs is a phase 2 interventional study registered as NCT04711135 by Advanced Accelerator Applications, with 11 participants enrolled, started 2022-08-31 and due to reach its primary completion in 2024-03-12. Interventions recorded: Lutetium [177Lu] oxodotreotide/dotatate. Conditions listed: Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma. Results were posted on ClinicalTrials.gov in 2024; the figures recorded here are the registry's, not a publication's.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT04711135","url":"https://clinicaltrials.gov/study/NCT04711135"}],"tags":["ctgov-ingest"],"related":[],"cancers":["pheochromocytoma-paraganglioma"],"sections":[],"technologies":["radioligand-therapy"],"targets":[],"drugs":["lutathera"],"companies":["novartis"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04711135","phase":"2","setting":"A Multicenter Open-label Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors, Pheochromocytoma and Paragangliomas (PPGL)","sponsor":"Advanced Accelerator Applications","started":"2022-08-31","startedType":"actual","yearReported":2024,"enrolled":11,"enrolledBasis":"registry","outcomes":[{"endpoint":"Absorbed Radiation Doses in Target Organ, Total Body","primary":true,"unit":"gy/gbq","arms":[{"name":"GEP-NET","n":4,"value":0.04,"note":"SD 0.013; Figures from the ClinicalTrials.gov results section (first posted 2024-11-27), not from a publication"},{"name":"PPGL","n":6,"value":0.041,"note":"SD 0.0073"}],"source":"https://clinicaltrials.gov/study/NCT04711135?tab=results"}]},"route":"/trials/nct04711135/","neighbours":{"cancer":[{"id":"pheochromocytoma-paraganglioma","kind":"cancer","name":"Pheochromocytoma and paraganglioma (PPGL)","route":"/cancers/pheochromocytoma-paraganglioma/"}],"technology":[{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/"}],"drug":[{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/"}],"company":[{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/"}]}}